Age-Related Macular Degeneration: Seven-Market Drug Forecast and Market Analysis

Description

List of Tables

The table below presents the key metrics for age-related macular degeneration (AMD) in the seven major pharmaceutical markets (7MM) covered in this report-the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan-during the forecast period from 2024-34.

In 2024, GlobalData estimated the total AMD market to be valued at $7.8 billion across the 7MM, with the US accounting for 67.2% of the market. The five major European markets (5EU) (France, Germany, Italy, Spain, and UK) accounted for 28.9% of the global AMD market with an estimated value of $2.2 billion, and Japan's AMD market was estimated to be $298.0 million in 2024, accounting for 3.8% of the market.

Over the forecast period, the AMD market is anticipated to grow to a value of $20.5 billion in 2034, with the US anticipated to account for 65.7% of the global market and a market value of $13.5 billion. The US market is anticipated grow at a CAGR of 10.0%, while the 5EU market is anticipated to grow at a CAGR of 10.9% to reach a market value of $6.3 billion in 2034. Japan is anticipated to witness the slowest growth among the 7MM with a CAGR of 8.9% during the forecast period and a market value of $702.1 billion in 2034.

Major drivers of growth in the AMD market during the forecast period include the following -

The launches of longer-acting anti-vascular endothelial growth factor (VEGF) therapies to treat patients with wet AMD (wAMD) and tyrosine kinase inhibitor (TKI) therapies
The availability of therapies for geographic atrophy (GA), which will increase the number of treatable cases of AMD
The launch of the first pharmacotherapy exclusively for early AMD, which will increase treatment options available for many patients with this sub-indication

Major barriers to growth in the AMD market during the forecast period will include the following:

Increased pressure to provide evidence of drug cost-effectiveness in the 7MM, which could complicate the reimbursement process of late-stage pipeline agents
The high annual cost of therapy (ACOT) of cell and gene therapies that are anticipated to launch within the forecast period and may cause payers to favor cheaper alternatives
Products that are due to lose exclusivity within the forecast period, and the subsequent launch of biosimilars

Scope

Overview of AMD, including epidemiology, symptoms, diagnosis, and disease management.
Annualized AMD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the AMD therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for AMD treatment. The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the global AMD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the 7MM AMD therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM AMD therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Product Code: GDHC328PIDR-7M

List of Tables

List of Figures

1 Age-Related Macular Degeneration: Executive Summary

1.1 AMD market will grow significantly during the forecast period, reaching sales of $20.5 billion in 2034
1.2 Development of cell-based and gene therapies represent a new paradigm for AMD
1.3 Reducing treatment burden is an important unmet need for wet AMD
1.4 Treatment for geographic atrophy and dry AMD represent an important unmet need for AMD
1.5 Late-stage pipeline therapies are anticipated to drive growth in the AMD market
1.6 What do physicians think?

2 Introduction

2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology
- 3.1.1 Overview
- 3.1.2 Etiology
- 3.1.3 Pathophysiology
3.2 Classification or staging systems

4 Epidemiology

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 7MM forecast methodology
- 4.4.1 Sources
- 4.4.2 Forecast assumptions and methods
- 4.4.3 Forecast assumptions and methods: diagnosed incident cases of AMD
- 4.4.4 Forecast assumptions and methods: total prevalent cases of AMD
- 4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of AMD, early AMD, late AMD, late dry AMD, and wet AMD
4.5 Epidemiological forecast for AMD (2024-34)
- 4.5.1 Diagnosed incident cases of AMD
- 4.5.2 Age-specific diagnosed incident cases of AMD
- 4.5.3 Sex-specific diagnosed incident cases of AMD
- 4.5.4 Diagnosed incident cases of early AMD
- 4.5.5 Diagnosed incident cases of late AMD
- 4.5.6 Diagnosed incident cases of late dry AMD
- 4.5.7 Diagnosed incident cases of wet AMD
- 4.5.8 Total prevalent cases of AMD
- 4.5.9 Age-specific total prevalent cases of AMD
- 4.5.10 Sex-specific total prevalent cases of AMD
- 4.5.11 Total prevalent cases of early AMD
- 4.5.12 Total prevalent cases of late AMD
- 4.5.13 Total prevalent cases of late dry AMD
- 4.5.14 Total prevalent cases of wet AMD
- 4.5.15 Diagnosed prevalent cases of AMD
- 4.5.16 Age-specific diagnosed prevalent cases of AMD
- 4.5.17 Sex-specific diagnosed prevalent cases of AMD
- 4.5.18 Diagnosed prevalent cases of early AMD
- 4.5.19 Diagnosed prevalent cases of late AMD
- 4.5.20 Diagnosed prevalent cases of late dry AMD
- 4.5.21 Diagnosed prevalent cases of wet AMD
4.6 Discussion
- 4.6.1 Epidemiological forecast insight
- 4.6.2 Limitations of the analysis
- 4.6.3 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview
5.2 KOL Insights on Disease Management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview
7.2 Longer treatment duration
7.3 Treatment for GA
7.4 Fibrosis prevention
7.5 Patient and healthcare system burden

8 R&D Strategies

8.1 Overview
- 8.1.1 Focus on the development of longer-acting therapies
- 8.1.2 Diversifying into cell and gene therapies for AMD
- 8.1.3 Development of novel mechanisms for AMD
8.2 Clinical trials design
- 8.2.1 Consideration of endpoints for the whole spectrum of AMD

9 Pipeline Assessment

9.1 Overview
9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview
10.2 Competitive assessment

11 Current and Future Players

11.1 Overview
11.2 Deal-making trends

12 Market Outlook

12.1 Global markets
- 12.1.1 Forecast
- 12.1.2 Drivers and barriers - global issues
12.2 US
- 12.2.1 Forecast
- 12.2.2 Key events
- 12.2.3 Drivers and barriers
12.3 5EU
- 12.3.1 Forecast
- 12.3.2 Key events
- 12.3.3 Drivers and barriers
12.4 Japan
- 12.4.1 Forecast
- 12.4.2 Key events
- 12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
- 13.3.1 Forecasting methodology
13.4 Primary research - KOLs interviewed for this report
- 13.4.1 KOLs
13.5 Primary research - prescriber survey
13.6 About the authors
- 13.6.1 Analyst
- 13.6.2 Therapy Area Director
- 13.6.3 Epidemiologist
- 13.6.4 Reviewers
- 13.6.5 Vice President of Disease Intelligence and Epidemiology
- 13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence
About GlobalData
Contact Us

Product Code: GDHC328PIDR-7M

List of Table

List of Tables

Table 1: AMD: key metrics in the 7MM
Table 2: Biological pathways associated with AMD risk genes
Table 3: The four-stage AREDS classification of AMD
Table 4: Symptoms of AMD
Table 3: Risk factors and comorbid conditions associated with AMD
Table 6: Treatment guidelines for AMD
Table 7: Top 10 deals by value, 2020-25
Table 8: AMD market - global drivers and barriers, 2024-34
Table 9: Key events impacting sales for AMD in the US, 2024-34
Table 10: AMD market - drivers and barriers in the US, 2024-34
Table 11: Key events impacting sales for AMD in the 5EU, 2024-34
Table 12: AMD market - drivers and barriers in the 5EU, 2024-34
Table 13: Key events impacting sales for AMD in Japan, 2024-34
Table 14: AMD market - drivers and barriers in Japan, 2024-34
Table 15: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figure

List of Figures

Figure 1: Global sales forecast by country for AMD in 2024 and 2034
Figure 2: Analysis of the company portfolio gap in AMD during the forecast period
Figure 3: Competitive assessment of late-stage pipeline agents that GlobalData expects to be licensed for the treatment of wAMD and GA during the forecast period
Figure 4: Comparison of the eye under normal vision and severe vision loss due to AMD
Figure 4: 7MM, diagnosed incidence of AMD, both sexes, ages >=50 years, cases per 100,000 population, 2024
Figure 5: 7MM, total prevalence of AMD, both sexes, ages >=50 years, %, 2024
Figure 6: 7MM, diagnosed prevalence of AMD, both sexes, ages >=50 years, 2024
Figure 7: 7MM, sources used and not used to forecast the diagnosed incident cases of AMD, early AMD, late AMD, late dAMD, and wAMD
Figure 8: 7MM, sources used and not used to forecast the total prevalent cases of AMD, early AMD, late AMD, late dAMD, and wAMD
Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of AMD, early AMD, late AMD, late dAMD, and wAMD
Figure 10: 7MM, diagnosed incident cases of AMD, N, both sexes, ages >=50 years, 2024
Figure 11: 7MM, age-specific diagnosed incident cases of AMD, both sexes, N, ages >=50 years, 2024
Figure 12: 7MM, sex-specific diagnosed incident cases of AMD, N, ages >=50 years, 2024
Figure 13: 7MM, diagnosed incident cases of early AMD, N, both sexes, ages >=50 years, 2024
Figure 14: 7MM, diagnosed incident cases of late AMD, N, both sexes, ages >=50 years, 2024
Figure 15: 7MM, diagnosed incident cases of late dAMD, N, both sexes, ages >=50 years, 2024
Figure 16: 7MM, diagnosed incident cases of wAMD, N, both sexes, ages >=50 years, 2024
Figure 17: 7MM, total prevalent cases of AMD, both sexes, ages >=50 years, N, 2024
Figure 18: 7MM, age-specific total prevalent cases of AMD, both sexes, N, ages >=50 years, 2024
Figure 19: 7MM, sex-specific total prevalent cases of AMD, N, ages >=50 years, 2024
Figure 20: 7MM, total prevalent cases of early AMD, both sexes, ages >=50 years, N, 2024
Figure 21: 7MM, total prevalent cases of late AMD, both sexes, ages >=50 years, N, 2024
Figure 22: 7MM, total prevalent cases of late dAMD, both sexes, ages >=50 years, N, 2024
Figure 23: 7MM, total prevalent cases of wAMD, both sexes, ages >=50 years, N, 2024
Figure 24: 7MM, diagnosed prevalent cases of AMD, both sexes, ages >=50 years, N, 2024
Figure 25: 7MM, age-specific diagnosed prevalent cases of AMD, both sexes, N, ages >=50 years, 2024
Figure 26: 7MM, sex-specific diagnosed prevalent cases of AMD, N, ages >=50 years, 2024
Figure 27: 7MM, diagnosed prevalent cases of early AMD, both sexes, ages >=50 years, N, 2024
Figure 28: 7MM, diagnosed prevalent cases of late AMD, both sexes, ages >=50 years, N, 2024
Figure 29: 7MM, diagnosed prevalent cases of late dAMD, both sexes, ages >=50 years, N, 2024
Figure 30: 7MM, diagnosed prevalent cases of wAMD, both sexes, ages >=50 years, N, 2024
Figure 23: Amsler grid, as viewed by patients with normal vision and with wAMD
Figure 24: Unmet needs and opportunities in AMD
Figure 25: Overview of the development pipeline in AMD
Figure 26: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for AMD in the 7MM during the forecast period
Figure 27: Competitive assessment of late-stage pipeline agents that GlobalData expects to be licensed for the treatment of wAMD and GA during the forecast period
Figure 28: Competitive assessment of the wAMD pipeline drugs benchmarked against the standard of care, Eylea, and GA pipeline drugs benchmarked against the standard of care, Izervay
Figure 29: Analysis of the company portfolio gap in AMD during the forecast period
Figure 30: Global (7MM) sales forecast by country for AMD in 2024 and 2034
Figure 31: Sales forecast by disease subtype for AMD in the US in 2034
Figure 32: Sales forecast for GA in the US in in 2024 and 2034
Figure 33: Sales forecast by class for wAMD in the US in 2024 and 2034
Figure 34: Sales forecast by disease subtype in the 5EU in 2034
Figure 35: Sales forecast by class for wAMD in the 5EU in 2024 and 2034
Figure 36: Sales forecast by class for wAMD in Japan in 2024 and 2034

Age-Related Macular Degeneration: Seven-Market Drug Forecast and Market Analysis

Description

Table of Contents

List of Tables

Scope

Reasons to Buy

Table of Contents

Table of Contents

List of Tables

List of Figures

1 Age-Related Macular Degeneration: Executive Summary

2 Introduction

3 Disease Overview

4 Epidemiology

5 Disease Management

6 Competitive Assessment

7 Unmet Needs and Opportunity Assessment

8 R&D Strategies

9 Pipeline Assessment

10 Pipeline Valuation Analysis

11 Current and Future Players

12 Market Outlook

13 Appendix

List of Table

List of Tables

List of Figure

List of Figures